Nave (@pme2717) 's Twitter Profile
Nave

@pme2717

stocks, politics , & a lot of controversial tweets.

ID: 382367563

calendar_today29-09-2011 23:21:10

12,12K Tweet

811 Takipçi

1,1K Takip Edilen

✪ Evil Te𝕏an ✪ (@viletexan) 's Twitter Profile Photo

I still can't get over the situation in Minnesota. They fucking imported 100,000 Somali's. Nobody in the fucking government questioned it. They put them all on SNAP and Welfare. Nobody in the fucking government stopped it. They gave them fake fucking daycare centers. Nobody in

Nave (@pme2717) 's Twitter Profile Photo

FSD with an impressive swerve around a BMW making last second turn into oncoming traffic over solid lines today. I was very impressed with the split second move & smoothness! MY HW4 V14.2.2.4 $TSLA Elon Musk Whole Mars Catalog Sawyer Merritt Tesla AI Tesla Owners Silicon Valley

Nave (@pme2717) 's Twitter Profile Photo

It’s actually shocking to me how many ppl are unaware of this. This is the single greatest athletic achievement ever. There’s nothing that even comes close IMO

Nave (@pme2717) 's Twitter Profile Photo

Our government is filled with nothing but losers. Billions in fraud & they can’t even keep the fucking airports working smooth. It’s beyond pathetic.

Zee C O N T R A R I A N (@zeecontrarian1) 's Twitter Profile Photo

$URGN - One of the brokers published today a survey among 36 leading urologists in the U.S. regarding their outlook on the future market distribution in NMIBC cancer. Although the broker does not cover URGN and tries not to mention its name, URGN’s Zusduri clearly dominates the

$URGN - One of the brokers published today a survey among 36 leading urologists in the U.S. regarding their outlook on the future market distribution in NMIBC cancer.

Although the broker does not cover URGN and tries not to mention its name, URGN’s Zusduri clearly dominates the
Zee C O N T R A R I A N (@zeecontrarian1) 's Twitter Profile Photo

I often say that price says everything, but there are sometimes anomalies in small caps. Check the case study of $URGN, which we recommended buying at $10 after it passed a Phase 3 trial. By the way, our base-case scenario now, after discussions with management, is that it gets